73 results
Page 2 of 4
8-K
EX-99.1
4pmkvjbxx o6l59bmzk1
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.2
8b0cvmb
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-99.1
nbjnbyuygte4jl
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
f9dx s8sll1yszdgc
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
6wz6xa8hlt5nlom24m
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
7uftl5kg2y3
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.2
0n8900 0rp0j8htz
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-99.1
m6r8ju
9 Nov 20
Cassava Sciences Reports Third Quarter 2020 Financial Results
8:30am
8-K
EX-99.1
rerdlarr8 iq4
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
85rn5 d6ghi
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
u171yk23so2mpp prju
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
ajj453cj23b334dogtyr
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
4tohu2sar go65xn5
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am
8-K
EX-99.1
fc3xk3 pftp3
6 May 20
Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business Update
8:16am
8-K
EX-99.1
qt75hbw8 off30ao4cl5
26 Mar 20
Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020
8:17am
8-K
EX-99.1
tpw0hv
27 Mar 19
Pain Therapeutics Announces Name Change to
3:02pm
8-K
EX-99.1
vtmgns9tu0t gzz
25 Mar 19
Pain Therapeutics Reports 2018 Financial Results and Corporate Update
12:00am